Unlocking the Full Potential of SGLT2 Inhibitors: Expanding Applications beyond Glycemic Control
International Journal of Molecular Sciences · 23.03.2023 · 24 (7) · 6039
DOI: 10.3390/ijms24076039 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 23.03.2023. Verfasst von Mahmoud E Youssef und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Faculty of Pharmacy, Delta University for Science and Technology, Gamasa 11152, Egypt. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 68-mal zitiert (Crossref) und nennt 174 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Oradea, Romania.
Abstract (Originalsprache)
The number of diabetic patients has risen dramatically in recent decades, owing mostly to the rising incidence of type 2 diabetes mellitus (T2DM). Several oral antidiabetic medications are used for the treatment of T2DM including, α-glucosidases inhibitors, biguanides, sulfonylureas, meglitinides, GLP-1 receptor agonists, PPAR-γ agonists, DDP4 inhibitors, and SGLT2 inhibitors. In this review we focus on the possible effects of SGLT2 inhibitors on different body systems. Beyond the diabetic state, SGLT2 inhibitors have revealed a demonstrable ability to ameliorate cardiac remodeling, enhance myocardial function, and lower heart failure mortality. Additionally, SGLT2 inhibitors can modify adipocytes and their production of cytokines, such as adipokines and adiponectin, which enhances insulin sensitivity and delays diabetes onset. On the other hand, SGLT2 inhibitors have been linked to decreased total hip bone mineral deposition and increased hip bone resorption in T2DM patients. More data are needed to evaluate the role of SGLT2 inhibitors on cancer. Finally, the effects of SGLT2 inhibitors on neuroprotection appear to be both direct and indirect, according to scientific investigations utilizing various experimental models. SGLT2 inhibitors improve vascular tone, elasticity, and contractility by reducing oxidative stress, inflammation, insulin signaling pathways, and endothelial cell proliferation. They also improve brain function, synaptic plasticity, acetylcholinesterase activity, and reduce amyloid plaque formation, as well as regulation of the mTOR pathway in the brain, which reduces brain damage and cognitive decline.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Faculty of Pharmacy, Delta University for Science and Technology, Gamasa 11152, Egypt.
- Department of Microbiology and Immunology, Faculty of Pharmacy, Zagazig University, Al Sharqia 44519, Egypt.
- Faculty of Medicine and Pharmacy, University of Oradea, P-ta 1 Decembrie 10, 410087 Oradea, Romania.
- Department of Pharmacology and Biochemistry, Faculty of Pharmacy, Horus University, New Damietta 34518, Egypt.
ORCID-Profile: Galal Yahya, Simona Cavalu, Sameh Saber
Förderung
- University of Oradea, Romania
Zitieren
APA
Youssef, M. E., Yahya, G., Popoviciu, M. S., Cavalu, S., Abd-Eldayem, M. A., & Saber, S. (2023). Unlocking the Full Potential of SGLT2 Inhibitors: Expanding Applications beyond Glycemic Control. International Journal of Molecular Sciences, 24(7), 6039. https://doi.org/10.3390/ijms24076039
Vancouver
Youssef ME, Yahya G, Popoviciu MS, Cavalu S, Abd-Eldayem MA, Saber S. Unlocking the Full Potential of SGLT2 Inhibitors: Expanding Applications beyond Glycemic Control. International Journal of Molecular Sciences. 2023;24(7):6039. doi:10.3390/ijms24076039
BibTeX
@article{Youssef2023,
author = {Youssef, Mahmoud E and Yahya, Galal and Popoviciu, Mihaela Simona and Cavalu, Simona and Abd-Eldayem, Marwa A and Saber, Sameh},
title = {Unlocking the Full Potential of SGLT2 Inhibitors: Expanding Applications beyond Glycemic Control},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {7},
pages = {6039},
doi = {10.3390/ijms24076039}
}
EUVIMED